A new report from the Peterson Health Technology Institute has concluded that many digital therapies for musculoskeletal (MSK) conditions like low back pain can deliver cl
The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig
One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<